FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108295228> ?p ?o ?g. }

• W2108295228 endingPage "385" @default.
• W2108295228 startingPage "382" @default.
• W2108295228 abstract "Purpose Intravenous vinorelbine has demonstrated its efficacy and tolerability in advanced non–small-cell lung cancer (NSCLC). An oral formulation of vinorelbine has been developed, and a number of phase II studies have shown its activity in chemotherapy-naive NSCLC, even in elderly patients, but no study has been performed to test activity and toxicity of oral vinorelbine in pretreated patients. The aims of our study were to investigate the activity and toxicity of oral vinorelbine in patients with NSCLC as salvage treatment. Patients and Methods Twenty pretreated patients with locally advanced (n = 6) and metastatic (n = 14) NSCLC entered the study. The schedule was oral vinorelbine 60 mg/m2 once a week until progression or development of unacceptable toxicity. Median age was 70 years (range, 49–84 years). Results Seventeen patients were evaluable for response and all for toxicity. A median of 9 cycles were administered (range, 2–21 cycles). No objective responses were reported, 5 patients experienced stable disease, and 12 patients had progressive disease. Median time to progression was 2 months (range, 1–6 months), and median survival was 4 months (range, 1–13 months). Treatment was well tolerated, with grade 4 neutropenia in 1 patient (heavily pretreated); grade 2 diarrhea in 2 patients; asthenia in 2 patients; and abdominal pain in 1 patient. Conclusion Oral vinorelbine 60 mg/m2 once a week is a very safe schedule in heavily pretreated locally advanced and metastatic NSCLC; however, at this dose, the drug is inactive. Other phase II studies with oral vinorelbine 80 mg/m2 weekly are warranted." @default.
• W2108295228 created "2016-06-24" @default.
• W2108295228 creator A5002072283 @default.
• W2108295228 creator A5003882744 @default.
• W2108295228 creator A5020053836 @default.
• W2108295228 creator A5038347927 @default.
• W2108295228 creator A5046163698 @default.
• W2108295228 creator A5052283742 @default.
• W2108295228 creator A5066253533 @default.
• W2108295228 creator A5067058355 @default.
• W2108295228 creator A5068204501 @default.
• W2108295228 creator A5073829389 @default.
• W2108295228 creator A5076440380 @default.
• W2108295228 creator A5091283268 @default.
• W2108295228 date "2007-05-01" @default.
• W2108295228 modified "2023-09-26" @default.
• W2108295228 title "A Phase II Study of Single-Agent Oral Vinorelbine in Patients with Pretreated Advanced Non–Small-Cell Lung Cancer" @default.
• W2108295228 cites W1839238860 @default.
• W2108295228 cites W1935885922 @default.
• W2108295228 cites W1964431856 @default.
• W2108295228 cites W1993310964 @default.
• W2108295228 cites W2037139573 @default.
• W2108295228 cites W2051263728 @default.
• W2108295228 cites W2066251854 @default.
• W2108295228 cites W2129793485 @default.
• W2108295228 cites W2141517959 @default.
• W2108295228 cites W2149756032 @default.
• W2108295228 cites W2154948351 @default.
• W2108295228 cites W2167805334 @default.
• W2108295228 cites W2169518833 @default.
• W2108295228 doi "https://doi.org/10.3816/clc.2007.n.019" @default.
• W2108295228 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17562239" @default.
• W2108295228 hasPublicationYear "2007" @default.
• W2108295228 type Work @default.
• W2108295228 sameAs 2108295228 @default.
• W2108295228 citedByCount "16" @default.
• W2108295228 countsByYear W21082952282012 @default.
• W2108295228 countsByYear W21082952282013 @default.
• W2108295228 countsByYear W21082952282014 @default.
• W2108295228 countsByYear W21082952282015 @default.
• W2108295228 countsByYear W21082952282017 @default.
• W2108295228 countsByYear W21082952282018 @default.
• W2108295228 countsByYear W21082952282020 @default.
• W2108295228 countsByYear W21082952282022 @default.
• W2108295228 crossrefType "journal-article" @default.
• W2108295228 hasAuthorship W2108295228A5002072283 @default.
• W2108295228 hasAuthorship W2108295228A5003882744 @default.
• W2108295228 hasAuthorship W2108295228A5020053836 @default.
• W2108295228 hasAuthorship W2108295228A5038347927 @default.
• W2108295228 hasAuthorship W2108295228A5046163698 @default.
• W2108295228 hasAuthorship W2108295228A5052283742 @default.
• W2108295228 hasAuthorship W2108295228A5066253533 @default.
• W2108295228 hasAuthorship W2108295228A5067058355 @default.
• W2108295228 hasAuthorship W2108295228A5068204501 @default.
• W2108295228 hasAuthorship W2108295228A5073829389 @default.
• W2108295228 hasAuthorship W2108295228A5076440380 @default.
• W2108295228 hasAuthorship W2108295228A5091283268 @default.
• W2108295228 hasConcept C126322002 @default.
• W2108295228 hasConcept C141071460 @default.
• W2108295228 hasConcept C143998085 @default.
• W2108295228 hasConcept C197934379 @default.
• W2108295228 hasConcept C2776256026 @default.
• W2108295228 hasConcept C2776694085 @default.
• W2108295228 hasConcept C2777063308 @default.
• W2108295228 hasConcept C2778239845 @default.
• W2108295228 hasConcept C2778375690 @default.
• W2108295228 hasConcept C2780350996 @default.
• W2108295228 hasConcept C29730261 @default.
• W2108295228 hasConcept C31760486 @default.
• W2108295228 hasConcept C71924100 @default.
• W2108295228 hasConcept C90924648 @default.
• W2108295228 hasConceptScore W2108295228C126322002 @default.
• W2108295228 hasConceptScore W2108295228C141071460 @default.
• W2108295228 hasConceptScore W2108295228C143998085 @default.
• W2108295228 hasConceptScore W2108295228C197934379 @default.
• W2108295228 hasConceptScore W2108295228C2776256026 @default.
• W2108295228 hasConceptScore W2108295228C2776694085 @default.
• W2108295228 hasConceptScore W2108295228C2777063308 @default.
• W2108295228 hasConceptScore W2108295228C2778239845 @default.
• W2108295228 hasConceptScore W2108295228C2778375690 @default.
• W2108295228 hasConceptScore W2108295228C2780350996 @default.
• W2108295228 hasConceptScore W2108295228C29730261 @default.
• W2108295228 hasConceptScore W2108295228C31760486 @default.
• W2108295228 hasConceptScore W2108295228C71924100 @default.
• W2108295228 hasConceptScore W2108295228C90924648 @default.
• W2108295228 hasIssue "6" @default.
• W2108295228 hasLocation W21082952281 @default.
• W2108295228 hasLocation W21082952282 @default.
• W2108295228 hasOpenAccess W2108295228 @default.
• W2108295228 hasPrimaryLocation W21082952281 @default.
• W2108295228 hasRelatedWork W2056002207 @default.
• W2108295228 hasRelatedWork W2066251854 @default.
• W2108295228 hasRelatedWork W2069238557 @default.
• W2108295228 hasRelatedWork W2075510991 @default.
• W2108295228 hasRelatedWork W2098897002 @default.
• W2108295228 hasRelatedWork W2108295228 @default.
• W2108295228 hasRelatedWork W2355731101 @default.
• W2108295228 hasRelatedWork W2367461116 @default.

• next